Ramses condoms' comparative strength claims "unsubstantiated" -- FTC consent agreement.
This article was originally published in The Gray Sheet
RAMSES CONDOM COMPARATIVE CLAIMS BARRED BY PROPOSED FTC AGREEMENT unless Norcross, Georgia-based London International "possesses and relies upon competent and reliable scientific evidence to back up the claims" for the latex condoms, the Federal Trade Commission reported Sept. 3. The consent agreement was spurred by advertising claims that Ramses is "30% stronger than the leading brand," which FTC called "unsubstantiated and deceptive."
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.